Applied Therapeutics, Inc. (NASDAQ:APLT) Given Average Recommendation of “Moderate Buy” by Brokerages

Applied Therapeutics, Inc. (NASDAQ:APLT) has earned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $6.10.

Several equities analysts recently weighed in on the company. Wall Street Zen raised Applied Therapeutics to a “sell” rating in a research note on Thursday, May 22nd. Royal Bank of Canada reiterated a “sector perform” rating and issued a $1.50 price objective on shares of Applied Therapeutics in a research report on Wednesday, May 14th.

Institutional Trading of Applied Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vestal Point Capital LP lifted its stake in shares of Applied Therapeutics by 904.4% during the 4th quarter. Vestal Point Capital LP now owns 11,500,000 shares of the company’s stock worth $9,846,000 after purchasing an additional 10,355,000 shares during the period. Propel Bio Management LLC lifted its holdings in shares of Applied Therapeutics by 17.4% during the 1st quarter. Propel Bio Management LLC now owns 11,285,420 shares of the company’s stock worth $5,517,000 after acquiring an additional 1,670,000 shares during the period. T. Rowe Price Investment Management Inc. boosted its position in shares of Applied Therapeutics by 91.5% in the first quarter. T. Rowe Price Investment Management Inc. now owns 10,380,590 shares of the company’s stock worth $5,076,000 after acquiring an additional 4,959,670 shares during the last quarter. VR Adviser LLC boosted its position in shares of Applied Therapeutics by 1.7% in the fourth quarter. VR Adviser LLC now owns 9,990,591 shares of the company’s stock worth $8,554,000 after acquiring an additional 165,591 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC grew its holdings in Applied Therapeutics by 2,458.3% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 8,762,291 shares of the company’s stock valued at $7,502,000 after purchasing an additional 8,419,781 shares during the period. 98.31% of the stock is owned by hedge funds and other institutional investors.

Applied Therapeutics Stock Up 1.5%

NASDAQ:APLT opened at $0.37 on Friday. The firm’s fifty day simple moving average is $0.39 and its 200-day simple moving average is $0.98. The stock has a market cap of $52.27 million, a PE ratio of -0.23 and a beta of 1.86. Applied Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $10.62.

Applied Therapeutics (NASDAQ:APLT) last issued its earnings results on Monday, April 14th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The business had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.61 million. Equities analysts anticipate that Applied Therapeutics will post -0.65 earnings per share for the current year.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.